Table 3. Clinical characteristics of patients with objective responses.

Age/sex	Baseline LDH	No. of prior therapies	Disease sites	Best response	Time-to-response (mos)	Response duration (mos)	OS (mos)
								76/M	113	3	Lung, soft tissue	irCRa	3.5	10.2+	13.7+
78/F	160	3	Lung, soft tissue, bone	irPR	2.4	2.8	8.3
62/M	92	4	Soft tissue	irCRb	5.2	6.2+	11.4+
66/M	121	2	Lung, soft tissue, lymph node	irCR	5.6	5.6+	11.2+
62/M	171	3	Lung, lymph node	irPR	4.3	6+	10.3+
47/M	210	1	Lymph node	irCRc	2.6	4.4+	7.0+

CR, complete response; LDH, lactate dehydrogenase; mos, months; OS, overall survival; PR, partial response

^aThis patient experienced a CR to ipilimumab and surgery;

^bThis patient received radiotherapy prior to study entry;

^cThis patient was found to have achieved a pathologic CR when the only metastatic site was resected.